Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Innovative therapies for neovascular age-related macular degeneration

Al-Khersan, Hasenin, Hussain, Rehan M., Ciulla, Thomas A., Dugel, Pravin U. · 2019 · Expert Opinion on Pharmacotherapy

Abstract

Introduction: Investigational anti-VEGF treatments for neovascular age-related macular degeneration (nAMD) aim to improve visual outcomes and reduce treatment burden; these include long-acting agents, combination strategies, topical agents, sustained-release, and genetic therapies.Areas covered: The authors provide a comprehensive review of investigational therapies for nAMD, focusing on therapies currently in clinical trial.Expert opinion: Long-acting anti-VEGF agents have demonstrated promising results in phase 3 studies, and include Brolucizumab, a single-chain antibody fragment, and Abicipar, a designed ankyrin repeat protein (DARPin). Other unique anti-VEGF agents in current trials include Conbercept – a fusion protein of the VEGF receptor domains, KSI-301 – an anti-VEGF antibody biopolymer conjugate, and OPT-302 – an inhibitor of VEGF-C/D. Strategies to activate the Tie-2 receptor, some in combination with VEGF inhibition, are of interest, with recent trials of Faricimab, ARP-1536, and nesvacumab. Topical anti-VEGF ± anti-PDGF agents, such as pazopanib, squalamine lactate, regorafenib, and LHA510 have shown limited efficacy and/or have not been advanced, although PAN-90806 continues to advance with promising initial results. Sustained-release anti-VEGF treatments, to address treatment burden, include the ranibizumab Port Delivery System, GB-102, NT-503, hydrogel depot, Durasert, and ENV1305. Similarly, genetic therapies, including RGX-314 and ADVM-022, aim to provide sustained anti-VEGF expression from the retina.

Overview

Integrity signals

Registry

Crossref · 10.1080/14656566.2019.1636031

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 69 references

Research works printed but not linked: 12

  1. Hjelmqvist L, 2011, J Ophthalmol, 405724
  2. Rakic JM, 2013, Clin Ophthalmol, 7, 1849
  3. Davis S, 1999, Curr Top Microbiol Immunol, 237, 173
  4. Dugel PU, 2018, Phase 3, randomized, double-masked, multicenter trials of brolucizumab vs. aflibercept for neovascular AMD: ninety-six-week results from the HAWK and HARRIER studies
  5. Dugel PU, 2017, HAWK & HARRIER: 48-week results of 2 multi-centered, randomized, double-masked trials of brolucizumab versus aflibercept for neovascular AMD
  6. Boyer DS, 2016, Aflibercept combination therapies: rinucumab/aflibercept and nesvacumab/aflibercept
  7. Helzner J, 2018, Retin Physician
  8. Khanani AM, 2018, Simultaneous inhibition of VEGF and Ang-2 with faricimab in neovascular AMD: STAIRWAY phase 2 results
  9. Rubio RG., 2014, Retina Today
  10. 2018, LADDER trial of the port delivery system for ranibizumab: preliminary study results
  11. Lurker N., 2016, Ophthalmic Innoviations Summit at American Academy of Ophthalmology meeting
  12. Moja L, 2014, Cochrane Database Syst Rev, 15, CD011230

Cited by

See all 114

Metadata

Authors
Al-Khersan, H., Hussain, R. M., Ciulla, T. A., & Dugel, P. U.
Affiliations
  • University of Miami (US)
  • Clearside Biomedical (United States) (US)
  • University of Southern California (US)
Corresponding author
Hussain, Rehan M.
Venue
Expert Opinion on Pharmacotherapy
Published
2019-07-12
Volume
20
Issue
15
Pages
1879-1891
ISSN
  • 1465-6566 (ISSN-L)
  • 1744-7666
OpenAlex
W2962115070
Cited by
114
References
69
Citations by year
2026: 5 · 2025: 9 · 2024: 11 · 2023: 13 · 2022: 21 · 2021: 28 · 2020: 24 · 2019: 3
FWCI
3.51
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Heidelberg Engineering
  • Allergan
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
neovascular age-related macular degeneration, anti-VEGF therapy, brolucizumab, conbercept, faricimab, sustained drug release, gene therapy, visual outcome
MeSH terms
Aged, Aged, 80 and over, Humans, Macular Degeneration, Angiogenesis Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Innovative therapies for neovascular age-related macular degeneration. https://app.cochat.ai/papers/10.1080/14656566.2019.1636031
The paper
Al-Khersan, H., Hussain, R. M., Ciulla, T. A., & Dugel, P. U. (2019). Innovative therapies for neovascular age-related macular degeneration. Expert Opinion on Pharmacotherapy. https://doi.org/10.1080/14656566.2019.1636031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.